Indeed, data from the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study), which investigated the use of canakinumab, an IL-1β blocker, in cardiovascular disease prevention, demonstrated that although the studied drug was profoundly neutropenic,38,39 it had no effect on BP,40 yet it should be emphasized that this was not a specific, neutrophil-targeting intervention. This evidence concerns the gene IL1B and cardiovascular disorder.